Baricitinib is a medicine used to treat rheumatoid arthritis and a kind of hair loss called alopecia areata. It is taken as a pill. It works by calming down parts of the immune system that cause swelling and attack the body.
Every report comes from a Lived member, sent anonymously.
Have you tried Olumiant (Baricitinib) for Alopecia Areata?
Baricitinib, sold under the brand name Olumiant, is a prescription tablet that turns down an overactive immune system. It belongs to a group of medicines called JAK inhibitors (short for Janus kinase inhibitors). In the US it is approved for three quite different situations. For rheumatoid arthritis, an autoimmune disease that inflames the joints, it treats moderately to severely active disease in adults who have already tried at least one TNF blocker (a biologic medicine that blocks tumor necrosis factor, an inflammatory signal) without enough benefit. It is not a first treatment for rheumatoid arthritis. It can be taken on its own or alongside methotrexate or similar non-biologic arthritis medicines. For severe alopecia areata, an autoimmune condition that causes hair loss, it is approved for adults and for children 12 and older. The studies behind this approval enrolled people who had lost at least half of their scalp hair, often along with eyebrows and eyelashes. Hospitals also use it for a short course in adults with COVID-19 who need oxygen or help breathing. That treatment is started and managed by the hospital team, so the rest of this page focuses on long-term use for arthritis and hair loss.
Immune cells communicate using signaling proteins called cytokines. When a cytokine attaches to the outside of a cell, enzymes inside the cell called Janus kinases (JAKs) pass the message along, switching on genes that drive inflammation and immune activity. Baricitinib blocks several of these enzymes, particularly JAK1 and JAK2. Because many different cytokines rely on the same relay, blocking it quiets a broad range of immune signals at once. In rheumatoid arthritis this reduces joint inflammation, pain and swelling. In alopecia areata it calms the immune activity that stops hair from growing, which allows regrowth in some people. The same signals also help the body fight infections and make blood cells. That is why the medicine's main risks, such as infections and changes in blood counts, come from the same effect that makes it work.
Baricitinib is a tablet taken once a day, with or without food. It comes in 1 mg, 2 mg and 4 mg strengths. For rheumatoid arthritis, the usual dose is 2 mg daily. For alopecia areata, treatment usually starts at 2 mg and can be raised to 4 mg if regrowth is not enough; people with nearly complete or complete scalp hair loss may start at 4 mg. Once hair has grown back well on 4 mg, the label advises stepping down to 2 mg. Lower doses are used when kidney function is reduced, and the dose is cut in half for people taking probenecid, a gout medicine that raises baricitinib levels in the blood. Before the first dose, the care team checks for tuberculosis (TB) and viral hepatitis, takes blood counts and liver and kidney tests, and brings vaccinations up to date. Anyone who cannot swallow tablets should ask about dispersing them in water rather than crushing them on their own.
The most common side effects in people treated for rheumatoid arthritis are colds and sinus infections, nausea, cold sores and shingles. In alopecia areata, headache, acne, higher cholesterol, urinary tract infections, inflamed hair follicles and tiredness are also common. Some effects show up only on blood tests, such as lower white or red blood cell counts, higher liver enzymes or higher cholesterol. Because the medicine weakens some immune defenses, infections can become serious. Call the care team right away for fever, chills, a new cough or shortness of breath, burning when urinating, or a painful blistering rash that could be shingles. Treatment is usually paused until an infection is under control. Rarely, the stomach or intestines can tear. Stomach-area pain that does not go away, especially with fever, chills, nausea or vomiting, needs medical help right away; the risk is higher in people with past diverticulitis or who also take anti-inflammatory painkillers, steroids or methotrexate. Stop the medicine and get emergency help for hives with trouble breathing, feeling faint, or swelling of the lips, tongue or throat. People with diabetes should watch for low blood sugar, which has been reported after starting JAK inhibitors.
Baricitinib carries the FDA's strongest warning, a boxed warning, covering five risks. Serious infections, including TB and fungal infections, have led to hospitalization or death. People who live in or have traveled to areas where certain fungal infections are common, such as the Ohio and Mississippi River valleys and the Southwest, should tell their prescriber. Lymphoma and other cancers, including skin cancers, have occurred. Blood clots in the legs or lungs happened more often with baricitinib than with TNF blockers in people with rheumatoid arthritis who were already at higher risk of clots. In a large study of a different JAK inhibitor in people with rheumatoid arthritis aged 50 or older with at least one heart risk factor, there were more deaths, heart attacks, strokes, lymphomas and lung cancers than with TNF blockers. Current or past smokers had the highest added risk. These findings are applied to the whole drug class, so the prescriber weighs them against the benefit, especially for older adults, smokers and anyone with heart disease, past clots or past cancer. Stop baricitinib and get emergency help for signs of a blood clot (leg swelling, pain or tenderness, sudden chest pain, or shortness of breath) or of a heart attack or stroke (chest pain or pressure, weakness on one side of the body, or slurred speech). Baricitinib is not meant to be combined with other JAK inhibitors, biologic medicines, or strong immune-suppressing drugs such as azathioprine and cyclosporine, because together they raise the risk of infection. Live vaccines should be avoided during treatment, so mention baricitinib before any vaccination. Animal studies suggest it may harm a developing baby and human data are limited, so anyone pregnant or planning pregnancy should discuss it with the prescriber. Breastfeeding is not advised during treatment or for 4 days after the last dose.
In rheumatoid arthritis, some people notice less joint pain and stiffness within the first week or two. Benefit is usually judged at about 12 weeks. In the main study of people who had already tried TNF blockers, about half improved by at least 20 percent on a standard arthritis score at 12 weeks, compared with about a quarter of those on a placebo; larger improvements were less common. In alopecia areata, regrowth is slow, and results were measured after about nine months (36 weeks). By then, roughly a third of adults on 4 mg and about a fifth on 2 mg had hair covering at least 80 percent of the scalp, compared with about 1 in 20 on placebo. In adolescents, the figures were 42 percent on 4 mg and 27 percent on 2 mg. People who started with less than near-total hair loss were more likely to respond, and eyebrows and eyelashes often improved too. Among adults who responded by one year and continued, about 85 percent kept their regrowth for around four years. Stopping usually reverses the benefit: in one trial, most people who stopped lost their regrowth over the following two years, though most regained it after restarting. Treatment involves ongoing blood tests to check blood counts and liver function, plus a cholesterol check about 12 weeks after starting. Regular skin checks are recommended for people at higher risk of skin cancer, and the care team keeps watching for TB even if the first test was negative.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Olumiant (Baricitinib), what you've noticed, or ask the community a question.